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REVIEW
Abstract: Pancreatic cancer is a largely chemo-resistant disease with a poor prognosis. Despite
the adoption of gemcitabine monotherapy as a standard of care, outcomes remain poor. Until
recently randomized phase III studies have not demonstrated superiority of various cytotoxic
combinations or a number of the newer biologic targeted drugs. The situation has changed
with capecitabine and erlotinib, either of which in combination with gemcitabine produces a
small increase in survival. Erlotinib is a small molecule tyrosine kinase inhibitor against
epidermal growth factor receptor which has an important role in the molecular pathogenesis
of pancreatic cancer. In both pre-clinical and early clinical evaluation it has shown anti-tumor
activity against pancreatic cancer in combination with gemcitabine. A randomized phase III
study in locally advanced and metastatic pancreatic cancer has shown a survival advantage
for the combination of gemcitabine plus erlotinib over gemcitabine alone. The rationale for
the clinical development of erlotinib in combination with gemcitabine in pancreatic cancer
culminating in this randomized trial, together with pharmacologic, toxicity and patient selection
considerations form the focus of this review.
Keywords: erlotinib, tarceva, capecitabine, xeloda, gemcitabine, epidermal growth factor
receptor, pancreas, pancreatic
Introduction
Pancreatic cancer is an aggressive malignancy, the vast majority of patients presenting
with advanced unresectable disease. Despite advances in the development of
conventional chemotherapy, notably the establishment of gemcitabine as a standard
of care, response rates to therapy are low and survival from the disease is still
depressingly poor. Gemcitabine gained favor in the treatment of advanced pancreatic
cancer worldwide after Burris et al (1997) reported the results of their randomized
controlled trial comparing gemcitabine, a novel nucleoside analogue with bolus 5-
fluorouracil (5-FU). This demonstrated significantly improved clinical benefit
response rates (24% vs 5%; p=0.0022) and median survival duration (5.65 vs 4.4
months; p=0.0025) for the gemcitabine arm. The one-year survival rate was 19% in
the gemcitabine group and only 2% in the 5-FU treatment group. The response rate
was 5.4% versus 0% (nonsignificant) and stable disease 39% versus 19% in favour
of gemcitabine. Despite the modest but significant increment in survival, gemcitabine
was adopted as the standard of care based on the significant improvement in clinical
benefit response which is a composite measure of pain (intensity and analgesic
requirement), performance status and weight. There are data suggesting that
modulating the rate of infusion of gemcitabine may enhance anti-tumor activity with
a randomized phase II study of fixed-dose rate gemcitabine given at an infusion rate
of 10 mg/m
2/min, demonstrating a trend towards improvement in response rate and
survival when compared with standard infusion of gemcitabine over thirty minutes
(Tempero et al 2003).
Gemcitabine has become the reference arm in randomized trials in the treatment
of advanced pancreatic cancer to which newer agents have been tested against either
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alone or in combination, particularly doublets. However,
several alternative cytotoxics as part of single agent or
combination therapies (usually doublets) have failed to
produce superior results over gemcitabine alone (Cheverton
et al 2004; Richards et al 2004; Rocha Lima et al 2004;
Louvet et al 2005). Recently a UK randomized phase III
study of 533 patients with advanced pancreatic cancer
reported significantly improved survival for the combination
of gemcitabine plus capecitabine over gemcitabine alone
with a median overall survival of 6.0 months versus 7.4
months in favor of the combination arm (hazard ratio [HR]
0.80; 95% confidence interval [CI]: 0.65, 0.98: p=0.026)
and 12 month survival of 19% and 26% respectively
(Cunningham et al 2005). Combination therapy was well
tolerated. This represents the first positive phase III study
demonstrating superiority of a cytotoxic doublet over
gemcitabine monotherapy. These results contrast with a
recently reported negative Swiss phase III study of
gemcitabine and capecitabine in which the doublet was
administered according to a different dosing and schedule
to that used in GEMCAP (Herrmann et al 2005).
There is still a clear need for new therapies and the
identification of novel therapeutic targets in an attempt to
improve on current standards. Within the last decade there
have been significant advances in our understanding of the
molecular pathogenesis underlying the development and
progression of pancreatic cancer. A greater understanding
of the interplay between tumor, stroma, and host and of
important genetic and epigenetic events has been vital in
identifying and developing potential therapeutic
interventions with the capacity to disrupt tumor progression.
A few randomized studies of gemcitabine versus
gemcitabine plus a biologic agent directed at promising
novel targets have proved negative (Bramhall et al 2001,
2002; Moore et al 2003; Van Cutsem et al 2004). The reasons
for this are unclear and for some of the candidate targets
may reflect that in metastatic pancreatic cancer, and indeed
many cancers, cell proliferation is likely to be dependent
on more than one genetic lesion such that growth control is
non-linear. The biologics have often been most successful
when targeting a critical genetic lesion upon which cellular
proliferation has become dependent, the notion of oncogene
addiction.
The contribution of the epidermal growth factor receptor
(EGFR) pathway to oncogenesis has been well documented
and therapeutic exploitation of this axis has proved to be a
successful strategy in several other tumor types including
colorectal and head and neck cancers. There has been
considerable interest in targeting the EGFR pathway in
advanced pancreatic cancer with agents such as erlotinib
currently in the limelight. The application of erlotinib to the
treatment of pancreatic cancer will be the focus of this review.
Targeting the epidermal growth
factor pathway in pancreatic
cancer
The erbB family of growth tyrosine kinase receptors
comprises four structurally homologous members including
erbB1, also known as the epidermal growth factor receptor
(EGFR), erbB2 (HER2/neu), erbB3 (HER3) and erbB4
(HER4) (Yarden and Sliwkowski 2001). ErbB tyrosine
kinase receptors are functionally inactive monomers that
contain an extracellular ligand binding domain, a single
hydrophobic transmembrane domain and an intracellular
tyrosine kinase domain. Binding of one of over ten cognate
ligands results in receptor homo- or hetero-dimerisation
mediated by cysteine rich loops in the ectodomain (Ogiso
et al 2002). The resulting phosphorylation of tyrosine
residues within the adenosine triphosphate (ATP) binding
kinase domain activates kinase activity and results in
phosphorylation of residues in the regulatory carboxyl
terminal tail of the receptor. This leads to the
phosphorylation, activation and recruitment of signaling
effectors containing SRC homology 2 and phosphotyrosine
binding domains that initiate a cascade of downstream
signaling events ultimately culminating in gene transcription
(Marmor et al 2004).
This complex network of erbB receptors, their associated
ligands, and the various signal processing pathways
contributes to the intricate regulation of normal cellular
processes including proliferation, differentiation, cell
motility, and survival. However, dysregulation of the
network can lead to aberrant control of cell growth which
may potentiate malignant transformation. Of the various
components of the network, abnormal signaling through the
erbB1 and erbB2 receptors has been most widely studied
and implicated in the pathogenesis of several tumor types
including pancreatic cancer. The EGFR, in particular, has
been selected as a rational target in the treatment of this
disease.
EGFR signaling in pancreatic
cancer
Aberrant signal transduction through EGFR and HER2
influences several processes pertinent to cancer progressionTherapeutics and Clinical Risk Management 2006:2(4) 437
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including proliferation, resistance to apoptosis, invasion,
angiogenesis, and metastasis. Dysregulation of the EGFR
signaling pathway may occur through various mechanisms
including receptor or ligand overexpression, receptor
mutation (as with EGFRvIII which has a truncated
extracellular domain and demonstrates constitutive ligand-
independent activation) and receptor crosstalk (Arteaga
2003). In contrast to receptor homodimerization, EGFR
heterodimerization, for instance with HER2, provides a
stronger mitogenic stimulus mediated predominantly
through the ras-raf mitogen activated protein kinase
(MAPK) and AKT-PI3-kinase (phosphatidylinositol 3-
kinase) pathways (Figure 1) (Mendelsohn and Baselga 2003;
Marmor et al 2004). The latter leads to degradation of the
inhibitory IKK protein and translocation of the nuclear factor
κB (NF-κB) into the nucleus where it activates transcription
of genes involved in cell survival and chemoresistance
(Guttridge et al 1999; Hinz et al 1999). The epidermal
growth factor has been shown to activate NF-κB in smooth
muscle cells, A431 cells, fibroblasts and estrogen receptor
negative, EGF-overexpressing breast cancer cell lines
(Habib et al 2001). HER2 has no cognate ligand but acts as
a dimerization partner for other members of the erbB family
utilizing the same effector signaling pathways and
strengthening the mitogenic stimulus through such means
as decreasing the rate of receptor downregulation and more
efficient coupling to signaling pathways (Marmor et al
2004).
Molecular dysfunction of the EGFR signal transduction
axis in pancreatic cancer can occur at several levels. A
significant proportion of pancreatic cancers demonstrate
increased expression of EGFR and its cognate ligand and
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Figure 1 The epidermal growth factor receptor pathway. Signaling through the epidermal growth factor receptor initiates a cascade intracellular cell signaling events
which result in proliferation, angiogenesis and cell survival.
Abbreviations: BAD, pro-apoptotic protein of the bcl-2 family; ERK: extracellular signal regulated kinase; GSK: glycogen synthase kinase; Mabs, monoclonal
antibodies; MEK: mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; NF-kB, nuclear factor-kappa B; PDK: 3-phosphoinositide dependent kinase;
PI3K, phopsphatidylinositol-3-kinase; PIP3: phosphatiyidylinositol (3,4,5)-triphosphate; PTEN, phosphatase and tensin homolog detected on chromosome 10; Ras/Raf:
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this has been correlated with enhanced tumor aggressiveness
and a worse prognosis (Lemoine et al 1992; Yamanaka et al
1993). Akt-2, a molecule downstream of PI3 kinase in the
EGFR signal cascade is overexpressed in up to 60% of
human pancreatic biopsies and the Akt-2 oncogene is
amplified in 10%–20% of pancreatic cancer cells (Ruggeri
et al 1998; Schlieman et al 2003). Akt has demonstrated
basal phosphorylation and activation in pancreatic cell lines
which may confer resistance to apoptosis (Bondar et al 2002;
Schlieman et al 2003). Akt activation may in some cases
result from loss of the inhibitory effect of PTEN and whilst
PTEN is not known to be mutated in pancreatic cancer, loss
of function could occur through alternative mechanisms
(Perren et al 2000; Ebert et al 2002). Further downstream
in the signaling cascade constitutive activation of the
transcription factor NF-κB has been identified in human
pancreatic cells and this may also enhance the drive for cell
survival (Wang et al 1999). EGFR signaling may also initiate
early malignant transformation via activation of the Notch
genes which are implicated in the regulation of cellular
differentiation during pancreatic organogenesis and their
activation can result in an expansion of undifferentiated cells
(Miyamoto et al 2003; Heiser and Hebrok 2004).
Modulation of EGFR-mediated signaling therefore
provides an attractive approach to the treatment of pancreatic
cancer. The two main therapeutic modalities used to target
the EGFR are monoclonal antibodies against the
extracellular domain and small molecules tyrosine kinase
inhibitors (TKIs) that compete at the ATP binding site of
the tyrosine kinase domain (Table 1). Of the latter, erlotinib
is the furthest in clinical development in pancreatic cancer.
Pre-clinical evaluation of erlotinib
Erlotinib (Tarceva; Genentech Inc, South San Francisco,
CA) is an orally available quinazoline-based small molecule
TKI with highly selective activity against the EGFR (in-
vitro IC50: 0.02 µmol/L; intact cells IC50: 0.2 µmol/L) (Moyer
et al 1997; Arteaga 2001). Examples of other small molecule
TKIs are provided in Table 1 and include some of the newer
dual or multi-targeted TKIs with activity against more than
one member of the erbB family of tyrosine kinase receptors.
In pre-clinical evaluation, erlotinib demonstrated anti-tumor
activity in a number of tumor xenograft models including
those modeling colon, head and neck and non small cell
lung cancers (Moyer et al 1997; Pollack et al 1999; Desai et
al 2002). Erlotinib was shown to inhibit EGFR activation
as well as to potentiate gemcitabine-induced apoptosis in
pancreatic carcinoma xenografts implanted orthotopically
into immunodeficient mice (Ng et al 2002). This
enhancement of gemcitabine-induced apoptosis by erlotinib
provides a reasonable scientific rationale for their
combination in clinical evaluation.
Further support for the therapeutic potential of combined
EGFR blockade and gemcitabine therapy has been derived
from pre-clinical studies of another EGFR inhibitor, the
monoclonal antibody C225 (the precursor of cetuximab);
in vitro, C225 was shown to exert anti-proliferative effects
on BxPC-3 human pancreatic cancer cells (Overholser et al
2000) and in an orthotopic nude mouse model of pancreatic
cancer the anti-tumor effects of C225 were potentiated by
the coadministration of gemcitabine (Bruns et al 2000).
Erlotinib has been combined with a number of other
cytotoxic agents in several pre-clinical models across tumor
types without the demonstration of antagonism and with no
clear demonstration of sequence-dependence (Akita and
Sliwkowski 2003).
The mechanism of action of erlotinib in terms of the
exact effects on downstream receptor signaling or activation
and mechanisms of resistance to the drug are still being
elucidated. Pharmacodynamic evaluation of erlotinib is
crucial to this process and will be discussed later. At a pre-
clinical level, one of the studies mentioned earlier
demonstrated reduction in phosphorylation of ERK1/2
(extracellular-regulated kinase), part of the ras-Raf
transduction effector cascade, in one of the xenograft models
with no effect on phospho-PKB (protein kinase B), part of
the PI3-kinase/Akt pathway, in either pancreatic xenograft
(Ng et al 2002).
Other potential cellular consequences of EGFR
suppression by erlotinib include the induction of G1 cell
cycle arrest possibly mediated through p27
KIP1, potentiation
of apoptosis by activation of pro-apoptotic molecules such
as bax and caspase-8, inhibition of angiogenesis through
Table 1 Therapeutic approaches to targeting the epidermal
growth factor receptor
Agent Characteristics
Cetuximab Chimeric human-mouse IgG1 Mab
Matuzumab (EMD 72000) Humanised IgG1 Mab
Panitumumab (ABX-EGF) Fully human IgG2 Mab
h-R3 Humanised IgG1 Mab
OSI-774 (Erlotinib) Reversible TKI
ZD-1839 (Gefitinib) Reversible TKI
EKB-569 Irreversible TKI
GW-016(Lapatinib) EGFR/HER2, reversibleTKI
CI-1033 Pan-erB TKI
Abbreviations: EGFR, epithelial growth factor receptor; IgG, immunogloblin;
Mab, monoclonal antibody; TKI, tyrosine kinase inhibitor.Therapeutics and Clinical Risk Management 2006:2(4) 439
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decreased production of growth factors such as vascular
endothelial growth factor (VEGF) and inhibition of invasion
and metastasis via inhibition of matrix metalloproteinases
(MMPs) (Mendelsohn and Baselga 2003). There is a strong
body of evidence to suggest EGFR suppression impairs the
ability of cells to repair cytotoxic or radiotherapy-induced
damage (Ciardiello et al 2000; Sirotnak et al 2000;
Mendelsohn and Baselga 2003). This together with
observations from pre-clinical studies suggests that the most
effective therapeutic application of this particular targeted
agent in advanced pancreatic cancer is as part of a
combinatorial strategy.
Another important consideration with regards to the
mode of action of EGFR inhibitors such as erlotinib is that
whilst these drugs have been designed to target the EGFR,
it appears that quantification of the target per se in pre-
clinical models may not predict for responsiveness to
inhibition. Erlotinib appears to inhibit both high and
moderate EGFR expressing tumor cell lines suggesting that
expression is not the only determinant of responsiveness to
erlotinib (Desai et al 2002). Although variability does exist
in EGFR quantification methodology, it is likely that other
factors such as receptor mutation, gene amplification,
dimerisation partners (such as Her2), receptor cross-talk and
alternative pathways for downstream activation may be
confounding factors. Taking these into account
quantification of EGFR status may not be reflective of
dependence of cell survival/proliferation on EGFR signaling
which may be a determinant of response to EGFR inhibitors.
Early phase studies: pharmacology
and pharmacokinetics
Four initial phase I trials, two of which were conducted in
volunteers, established preliminary pharmacokinetic (PK)
data for erlotinib (Hidalgo et al 2001; Hidalgo and Bloedow
2003). These demonstrated rapid absorption with peak
plasma concentrations occurring within 4 hours, dose
dependent PK between 3 mg to 30 mg but non-linear PK at
higher doses, drug accumulation and continuous exposure
with daily treatment (Hidalgo et al 2001; Hidalgo and
Bloedow 2003). The phase I study that established the
current recommended dosing for erlotinib was performed
in patients with advanced, refractory solid tumors and
explored a daily dosing of dose-escalated erlotinib according
to three different schedules (Hidalgo et al 2001). A daily
dosing schedule was established as tolerable with PK
indicating increased plasma levels of erlotinib with
escalating doses and no unexpected drug accumulation.
Erlotinib appeared to be well tolerated and diarrhea and
acneiform skin rash were defined as the dose-limiting
toxicities, dose-limiting diarrhea occurring at the 200 mg/
day dose. At a dose of 150mg/day diarrhea appeared to be
manageable as was acneiform rash which was seen to occur
at all doses of erlotinib. This dose was subsequently
recommended as the dose to be taken forward in further
clinical evaluation.
On a continuous dosing schedule, the steady state was
reached in seven days with a half life of approximately 18
hours (Hidalgo et al 2001). Further support for the 150 mg/
day dosing was provided by the fact that the minimum
plasma concentration at this dose exceeded 500 mg/mL,
which is the concentration associated with EGFR inhibition
and anti-tumor activity in pre-clinical studies (Hidalgo et al
2001). Plasma concentrations in this range were seen less
frequently with dosing of 50 mg or 100 mg per day.
Erlotinib undergoes hepatic metabolism, 80% occurring
via cytochrome CYP3A4 which is commonly involved in
the hepatic metabolism of several other drugs thereby
increasing the potential for drug-drug interaction (Hidalgo
and Bloedow 2003). In particular potent 3A4 inhibitors such
as ketoconazole, certain other anti-fungals (fluconazole and
itraconazole) and antibiotics (ie, erythromycin) may increase
exposure to erlotinib whilst potent 3A4 inducers such as
rifampicin and some anti-epileptic drugs will reduce
exposure (Abbas et al 2003). Caution should be exercised
when co-administering these drugs with erlotinib,
particularly the CA4 inhibitors, and dose adjustment of the
erlotinib may be necessary. The predominant metabolite of
erlotinib is OSI-420 which has a similar pharmacokinetic
profile to erlotinib, also inhibits EGFR and undergoes biliary
excretion (Moyer et al 1997).
Combination of cytotoxics with other agents such as
erlotinib is intuitively attractive in terms of the potential for
targeting different oncogenic processes, avoiding
development of resistance, potential for synergy and the
resultant possible enhancement of anti-tumor effect therein.
The pre-clinical rationale for combining gemcitabine with
erlotinib has already been stated. In phase I evaluation in
patients with pancreatic cancer, the combination of
gemcitabine administered according to the standard schedule
plus erlotinib at doses of 100 mg/day or 150 mg/day was
found to be tolerable with no dose-limiting toxicity or
significant pharmacokinetic interactions (Dragovich et al
2003; Porterfield et al 2004). In another phase I study, the
combination of erlotinib with the chemotherapy doublet
gemcitabine (according to a standard schedule) and cisplatinTherapeutics and Clinical Risk Management 2006:2(4) 440
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in patients with advanced solid tumors was tolerable and
did not indicate significant pharmacokinetic interactions
(Ratain et al 2002). These studies provide support for
evaluation of a gemcitabine-based chemotherapy plus
erlotinib in the treatment of pancreatic cancer.
Erlotinib in combination with
chemotherapy in clinical studies
Initially erlotinib was evaluated as monotherapy in phase II
studies across a broad range of tumor types including lung,
ovary, colorectal, and head and neck cancer (Herbst 2003;
Shepherd et al 2004; Soulieres et al 2004) with the
demonstration of responses and induction of stable disease
in several of these studies. Notably, the demonstration of
single agent activity for erlotinib in the treatment of chemo-
refractory lung cancer led to regulatory approval for this
indication. Toxicities were in line with those seen in earlier
phase I evaluation.
In pancreatic cancer, clinical evaluation of erlotinib has
been undertaken as part of a combination approach with
gemcitabine. The National Canadian Institute of Cancer
(NCIC) conducted an international, multicenter randomized
placebo controlled phase III trial (PA.3) of gemcitabine
versus gemcitabine in combination with erlotinib in
advanced pancreatic cancer (Moore et al 2005). 569 patients
were randomized to receive either gemcitabine, which was
administered at a dose of 1000 mg/m
2 over 30 minutes given
weekly for seven weeks then for three out of every four
weeks thereafter or gemcitabine (same schedule) plus
erlotinib. The starting dose of erlotinib in the combination
arm was 100 mg/day based on the potential for additive
toxicity. After several planned safety reviews, including a
review of toxicity by the Drug Safety Monitoring
Committee, a smaller final cohort of patients received the
higher dose of 150 mg daily. Expression of EGFR was not
mandated for trial entry although this information was
collected. Patient characteristics were well balanced and
approximately 25% of patients in both arms had locally
advanced disease.
Overall survival was significantly better in the erlotinib
arm compared with the placebo controlled arm with a median
survival of 6.37 versus 5.91 months (HR 0.81; 95% CI 0.67,
0.97; p=0.025) and one year survival of 24% versus 17%
respectively. Whilst the difference in median survival
appears small, it should be noted that the survival curves
came closer together for this point estimate and that the HR
is probably more representative of the overall difference
between the two arms. Similarly, progression-free survival
was significantly improved in the combination arm, the
medians being 3.75 versus 3.55 months respectively
(HR=0.76; 95% CI 0.63, 0.91; p=0.003). Overall response
rate did not appear to be different between the combination
and placebo controlled arms (8.6% vs 8.0% respectively)
although disease control did appear different (57.5% vs
49.2%). Toxicity will be discussed later but skin rash and
diarrhea appeared to be increased in the erlotinib arm.
Quality of Life assessment was undertaken in the North
American centers according to the EORTC QLQ-c30 and
indicated that per cycle there was a significant difference in
favor of the placebo controlled arm in terms of diarrhea.
There were no significant differences for global quality of
life scores (Moore et al 2005). Although the survival
increment in this study was small, it is now one of two
positive randomized studies demonstrating a survival benefit
for combining gemcitabine with another agent, importantly
a biologic response modifier. The study also led to regulatory
approval for the combination of gemcitabine and erlotinib
in advanced pancreatic cancer in the US in November 2005.
Given that the majority of patients had been treated with
the 100 mg dose in the trial, this has been recommended as
the combination dose.
These results are in contrast to those observed in two
randomized studies of chemotherapy doublets plus or minus
erlotinib in over 1000 patients each (TRIBUTE and
TALENT) performed in chemonaive lung cancer patients
(Gatzemeier et al 2004; Herbst, Johnson, et al 2005).
Importantly, presence of EGFR mutations in the tyrosine
kinase domain and other molecular aberrations in lung
cancer patients are associated with response/resistance to
EGFR TKIs (Lynch et al 2004; Eberhard et al 2005) and
therefore the lack of selection for potential responders may
have diluted any therapeutic effect of erlotinib in these large
studies. EGFR mutations have not been found in pancreatic
cancers and this is therefore unlikely to be a molecular
marker that could potentially facilitate better selection of
patients for erlotinib therapy. This will be discussed in more
detail in later.
Combination of erlotinib with an effective cytotoxic
doublet such as gemcitabine plus capecitabine would appear
to be an attractive therapeutic option. Furthermore
combination of erlotinib with another biologic agent such
as the anti-VEGF agent bevacizumab, also appears
attractive. In colon and gastric cancer cell lines, combined
blockade of EGFR and VEGF resulted in significant anti-
tumor responses which were greater than suppression of
one pathway alone (Ciardiello et al 2000; Jung et al 2002).Therapeutics and Clinical Risk Management 2006:2(4) 441
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In a phase I/II study in lung cancer, the combination of
erlotinib and bevacizumab was tolerable, had no
pharmacokinetic interaction and importantly resulted in
responses in the absence of cytotoxic treatment (Herbst,
Prager, et al 2005). Currently, there is an international
placebo controlled phase III study underway comparing the
combination of gemcitabine plus erlotinib according to the
PA.3 schedule versus gemcitabine, erlotinib plus
bevacizumab in patients with metastatic pancreatic cancer
(Figure 2), the results of which should prove very interesting.
The erlotinib dose being used is 100 mg/day and the study
is powered to demonstrate a survival difference between
the arms.
At the Royal Marsden Hospital, UK, a phase I/II study
(TARGET) is exploring the combination of gemcitabine,
capecitabine (according to the GEMCAP schedule) plus
erlotinib and bevacizumab in locally advanced and
metastatic pancreatic cancer. It is likely that these multi-
agent, multi-targeted approaches will be increasingly
investigated in the treatment of advanced pancreatic cancer.
In addition studies of alternative EGFR inhibitors in the
first-line treatment of advanced pancreatic cancer are in
progress with the randomised phase III Southwest Oncology
Group (SWOG) trial of gemcitabine versus gemcitabine plus
cetuximab having recently completed accrual. In a
randomized phase II study performed by the University of
Chicago, patients with advanced pancreatic cancer are
randomized between gemcitabine, bevacizumab and
erlotinib or gemcitabine, bevacizumab and cetuximab which
will facilitate selection of a future comparator arm for phase
III evaluation.
Toxicities associated with erlotinib
Skin rash
A class effect of EGFR inhibitors such as erlotinib and
indeed the monoclonal antibodies is the development of a
skin rash characterized by clusters of monomorphic pustular
lesions and which is often likened to an acneiform eruption.
The distribution of the rash is usually limited to the face
and upper torso and although grading in the Common
Toxicity Criteria version 2.0 categorizes rash according to
percentage of body distribution, the latest version, 3.0,
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perhaps more appropriately allows grading of acneiform rash
according to the need for medical intervention, although
even the latest classification is not ideal.
Other dermatological manifestations of EGFR inhibition
include dry skin, pruritis, erythema and nail, hair and eyelash
changes (Perez-Soler and Saltz 2005). The onset of rash is
usually within the first two weeks of therapy and often
improves despite further continuous dosing (Hidalgo et al
2001). Erlotinib-induced rash also appears to be dose-
dependent (Hidalgo et al 2001) in line with the dose-
dependence demonstrated for another EGFR TKI in clinical
use, gefitinib (Perez-Soler and Saltz 2005). The rash is
usually well tolerated but when associated with symptoms
such as itching or supra-added infection can be very
problematic. Furthermore, the cosmetic appearance of the
rash can be unacceptable to the patient and impact on their
quality of life.
In the initial phase I studies biopsy of affected areas revealed
neutrophil infiltration of dermal tissues, particularly in relation
to the infundibular portion of the hair follicle, and thinning of
the stratum corneum layer of the epidermis (Hidalgo et al 2001;
Malik et al 2003). The etiology of this skin reaction is not
entirely clear but may relate to disruption of EGFR signaling
in the dermis. EGFR is expressed in normal keratinocytes, skin
fibroblasts, and in the outer route sheath of the hair follicle and
is likely to have a physiological role in maintenance of the
epidermis and skin/hair development (King et al 1990; Hansen
et al 1997). Alternatively, EGFR inhibition may induce a local
or systemic inflammatory skin reaction (Perez-Soler and Saltz
2005).
Pharmacogenomics may play a role in the inter-patient
variability of rash development with a recent study
suggesting the number of germline polymorphic CA
dinucleotide repeats in intron 1 of the EGFR gene may be
associated with response to EGFR inhibition and rash; cell
lines (mainly head and neck) demonstrating fewer than 36
CA repeats were more sensitive to inhibition by erlotinib
than those with greater than or equal to 36 CA repeats
(Amador et al 2004). In the same study, a smaller number
of CA repeats appeared to correlate with development of
skin rash in patients with colorectal cancer (n=19) treated
with gefitinib. These results are of interest and importantly
indicate a potential mechanism for the association of rash
with outcome which will be discussed further, but do require
validation in larger studies.
The therapeutic management of EGFR inhibitor-induced
skin rash has generated significant debate and there are
currently no evidence-based guidelines for treatment. A
variety of dermatological interventions have been employed
including topical and systemic antibiotics, retinoids,
corticosteroids and emollients with varying degrees of
success (Perez-Soler and Saltz 2005; Segaert and Van
Cutsem 2005). Certainly where there is clear evidence of
supra-added infection, antibiotics may be beneficial.
Otherwise, experience with all these agents is largely
anecdotal and there is a clear need for systematic evaluation
of interventions within controlled trials.
Other toxicities
Other commonly observed toxicities in the phase I studies
and the Canadian phase III study were diarrhea, headache,
nausea, vomiting, fatigue and mucositis (Hidalgo et al 2001;
Dragovich et al 2003; Porterfield et al 2004; Moore et al
2005). Table 2 demonstrates the toxicities seen in the NCIC
study. Apart from skin rash, the rate of grade 3/4 diarrhea
was different between the arms being 6% in the gemcitabine/
erlotinib arm and 2% in the gemcitabine/placebo arm.
Erlotinib-induced diarrhea should be managed aggressively
with medical assessment, admission and the use of anti-
diarrheal agents and parenteral fluids as necessary. Both
gemcitabine and erlotinib can cause interstitial fibrosis
(pneumonitis) and in the NCIC study this occurred in 2%
of patients receiving combination therapy compared with
<1% who received gemcitabine alone. The overall toxicity
profile of erlotinib in combination with gemcitabine,
however, appears to be tolerable.
Selection of patients for therapy
The issue of patient selection with targeted agents is
important in terms of optimizing the chance of response to
therapy, limiting exposure to drugs that do add additional
toxicity and to help rationalize resources. As discussed
earlier, skin rash may be a surrogate marker of outcome to
EGFR inhibitors such as erlotinib. Although this association
has been less consistent with other EGFR TKIs such as
gefitinib (Perez-Soler and Saltz 2005) it appears to be
stronger with erlotinib as demonstrated in a number of trials,
predominantly in lung cancer (Gatzmeier et al 2004; Herbst,
Johnson, et al 2005; Perez-Soler and Saltz 2005). Not only
the presence but the intensity of skin rash appeared to
correlate with survival in these trials. Certainly in the NCIC
Phase III study in pancreatic cancer, sub-group analysis also
suggested an association with skin rash and survival; median
survival for patients with grade 0 skin rash (n=79) was 5.29
months, with grade 1 skin rash (n=108) was 5.75 months
and with grade 3 skin rash (n=103) was 10.51 monthsTherapeutics and Clinical Risk Management 2006:2(4) 443
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(Moore et al 2005). The difference in survival between
patients who developed grade 2 rash compared with grade
0/1 was statistically significant (p<0.0001). However,
titration of erlotinib to skin rash in an attempt to optimize
efficacy is likely to be difficult given that diarrhea has been
demonstrated as the main dose-limiting toxicity. A dose-to-
rash study is currently ongoing with erlotinib in lung cancer
to explore this issue further (Mita et al 2005).
Several pharmacodynamic studies have been undertaken,
often using skin as a surrogate tissue for response, in order
to identify molecular aberrations in the EGFR pathway that
may indicate response or resistance to therapy (Albanell et
al 2002; LoRusso 2003; Malik et al 2003). However, whilst
these often reveal interesting hypothesis-generating
observations, none has identified a marker that has
immediate clinical utility (Abanell et al 2002; Malik et al
2003). Furthermore, molecular changes occurring in
response to EGFR suppression in the skin may not mirror
changes in the tumor for a number of reasons including
differences in EGFR dimerization partners and the presence
of somatic mutations (Baselga 2003; Laux et al 2006).
Across studies and tumor types, there has consistently
been a lack of association between EGFR expression, as
judged by immunohistochemistry, and response to therapy
in line with the pre-clinical observations (Desai et al 2002;
Herbst 2003; Hortobagyi and Sauter 2003). In the NCIC
study in pancreatic cancer, EGFR expression did not
correlate with survival by treatment arm with the cut-off
for EGFR positive tumors being 10% membranous staining
(Moore et al 2005). Selection for erlotinib therapy in
pancreatic cancer should not be made on the basis of EGFR
expression by immunohistochemistry. At the present time,
there are no validated predictive markers that allow
rationalization of erlotinib use in pancreatic cancer but work
in this area is ongoing.
Conclusion
Erlotinb in combination with gemcitabine has recently been
shown to be superior to gemcitabine monotherapy with a very
modest improvement in survival. There are now two positive
randomized phase III trials which have demonstrated a survival
advantage for gemcitabine-based combination therapy, one
incorporating a cytotoxic agent (Cunningham et al 2005) and
the other, a biologic agent directed against the EGFR pathway
(Moore et al 2005). Both represent important, albeit small, steps
in improving outcome from this aggressive malignancy and
the latter importantly validating an approach that has been
rationally selected based on the perceived importance of one
of the pathophysiological mechanisms underlying the disease.
Both could be considered standard treatment options for
advanced pancreatic cancer. However, quality of life and
pharmacoeconomic considerations are likely to dictate the
uptake of either approach and the latter are yet to be undertaken.
Ongoing and future studies in advanced pancreatic cancer are
building on combinatorial approaches and the next generation
of trials are incorporating biologic agents with conventional
cytotoxics and additionally combining biologic agents. This
multi-targeted approach may ultimately prove more effective
in treating what is effectively a chemo-resistant disease. Given
the efficacy of erlotinib demonstrated in the Canadian trial,
erlotinib or alternative EGFR inhibitors such as cetuximab,
are likely to be part of this strategy.
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